Sun Di, Zhou Bing-Yang, Zhao Xi, Li Sha, Zhu Cheng-Gang, Guo Yuan-Lin, Gao Ying, Wu Na-Qiong, Liu Geng, Dong Qian, Li Jian-Jun
Division of Dyslipidemia, State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
J Clin Lab Anal. 2018 Sep;32(7):e22442. doi: 10.1002/jcla.22442. Epub 2018 Mar 30.
Lipoprotein(a) [Lp(a)] level is a novel risk factor for atherosclerotic cardiovascular disease in patients with familial hypercholesterolemia (FH), while its impact on the different sites of arteries remains undetermined. We aim to examine the associations of Lp(a) levels with coronary and carotid atherosclerosis in patients with heterozygous FH (HeFH).
A total of 148 patients with HeFH who have received carotid ultrasonography and coronary angiography due to chest pain were enrolled. Plasma Lp(a) was measured using immunoturbidimetric method. Finally, the associations between Lp(a) and coronary as well as carotid lesions were evaluated.
Patients with Lp(a) ≥ 300 mg/L had similar carotid intima-media thickness (IMT, 0.782 ± 0.16 mm vs 0.798 ± 0.18 mm, P = .579) and plaque prevalence (66.7% vs 65%, P = .833) compared to those with Lp(a) < 300 mg/L, but had a higher prevalence of coronary artery disease (CAD, 69.7% vs 50.0%, P = .016) and higher Gensini score (GS, median 27 vs 3, P = .006). Moreover, no correlations were found between carotid mean IMT with either Lp(a) level or Lp(a) year score, while positive relation of Lp(a) with GS did. Multivariate regression analysis revealed that Lp(a), Lp(a) year score, and Lp(a) ≥ 300 g/L were all independent predictors for the presence of CAD (OR = 4.99, P = .007; OR = 4.73, P = .009; OR = 4.46, P = .006, respectively) but not for carotid plaques.
This study suggested that Lp(a) level was associated with the presence and severity of CAD but not with carotid atherosclerosis in patients with HeFH.
脂蛋白(a)[Lp(a)]水平是家族性高胆固醇血症(FH)患者动脉粥样硬化性心血管疾病的一个新的危险因素,但其对动脉不同部位的影响仍未确定。我们旨在研究杂合子FH(HeFH)患者Lp(a)水平与冠状动脉和颈动脉粥样硬化的相关性。
共纳入148例因胸痛接受颈动脉超声检查和冠状动脉造影的HeFH患者。采用免疫比浊法测定血浆Lp(a)。最后,评估Lp(a)与冠状动脉及颈动脉病变之间的相关性。
与Lp(a)<300mg/L的患者相比,Lp(a)≥300mg/L的患者颈动脉内膜中层厚度(IMT,0.782±0.16mm vs 0.798±0.18mm,P = 0.579)和斑块患病率(66.7% vs 65%,P = 0.833)相似,但冠状动脉疾病(CAD)患病率更高(69.7% vs 50.0%,P = 0.016),Gensini评分(GS)更高(中位数27 vs 3,P = 0.006)。此外,未发现颈动脉平均IMT与Lp(a)水平或Lp(a)年评分之间存在相关性,而Lp(a)与GS呈正相关。多因素回归分析显示,Lp(a)、Lp(a)年评分和Lp(a)≥300mg/L均为CAD存在的独立预测因素(OR分别为4.99,P = 0.007;OR = 4.73,P = 0.009;OR = 4.46,P = 0.006),但不是颈动脉斑块的独立预测因素。
本研究表明,HeFH患者的Lp(a)水平与CAD的存在和严重程度相关,但与颈动脉粥样硬化无关。